Catalyst Pharmaceuticals, Inc. Shares Sold by Ikarian Capital LLC

CPRX Stock  USD 21.34  0.63  2.87%   
Slightly above 58% of Catalyst Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Catalyst Pharmaceuticals suggests that many traders are alarmed. Catalyst Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Catalyst Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
  
Ikarian Capital LLC cut its position in Catalyst Pharmaceuticals, Inc. by 19.4 percent during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission . The fund owned 417,850 shares of the biopharmaceutical companys stock after selling 100,536 shares during the period. Catalyst Pharmaceuticals accounts

Read at thelincolnianonline.com
news
  

Catalyst Pharmaceuticals Current Investor Sentiment

Panic Vs Confidence

42

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Catalyst Pharmaceuticals' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Catalyst Pharmaceuticals.

Catalyst Pharmaceuticals Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Catalyst Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Catalyst Pharmaceuticals Fundamental Analysis

We analyze Catalyst Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Catalyst Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Catalyst Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Number Of Employees

Number Of Employees Comparative Analysis

Catalyst Pharmaceuticals is currently under evaluation in number of employees category among its peers. Number of Employees shows the total number of permanent full time and part time employees working for a given company and processed through its payroll.

Catalyst Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Catalyst Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Catalyst Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Catalyst Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Catalyst Pharmaceuticals Related Equities

HEPAHepion Pharmaceuticals   5.08   
0%
24.0%
INZYInozyme Pharma   0.68   
0%
3.0%
TGTXTG Therapeutics   0.06   
1.0%
0%
EXELExelixis   0.68   
3.0%
0%
SRPTSarepta Therapeutics   0.73   
3.0%
0%
MDGLMadrigal Pharmaceuticals   1.33   
6.0%
0%
TERNTerns Pharmaceuticals   1.64   
7.0%
0%
INCYIncyte   2.29   
10.0%
0%
DAWNDay One   2.66   
12.0%
0%
VKTXViking Therapeutics   2.72   
12.0%
0%
MREOMereo BioPharma   3.12   
14.0%
0%
AXSMAxsome Therapeutics   3.45   
16.0%
0%
ACADACADIA Pharmaceuticals   4.22   
20.0%
0%
AKROAkero Therapeutics   4.35   
20.0%
0%
BTAIBioXcel Therapeutics   4.65   
22.0%
0%
XFORX4 Pharmaceuticals   21.05   
100.0%
0%

Additional Tools for Catalyst Stock Analysis

When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.